Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer

Abstract

MicroRNA-195 (miR-195) is a tumor suppressor that plays an important role in tumorigenesis. There are few studies on miR-195 expression in breast cancer patients and the results have been inconsistent; therefore, this study examined miR-195 expression in the serum of BC patients. Samples from 102 normal subjects and 210 subjects with BC who had detailed clinical follow-up information available were selected. An internal reference (miR-16) and serum miR-195 were amplified and quantitatively detected by SYBR green-based real-time RT-PCR. We analyzed the differences in miR-195 levels between BC and healthy cases and the relationships between the miR-195 level and TNM stage and other clinicopathological parameters. In addition, changes in miR-195 levels were examined for 21 BC cases using paired samples before and after neoadjuvant chemotherapy. miR-195 was downregulated in BC compared with control samples (P = 0.000, Mann-Whitney U test). The sensitivity and specificity of miR-195 in the diagnosis of BC were 69.0 and 89.2 %, respectively; whereas, the sensitivities of carcinoembryonic antigen (CEA) and carbohydrate antigen 153 (CA153) were only 15.08 and 21.1 %, respectively. Remarkably, serum miR-195 had higher sensitivity, 73.97 % (108/146), as a tumor marker in the diagnosis of early stage BC [ductal carcinoma in situ, tumor-node-metastasis (TNM) I, II] compared with the conventional tumor markers CA153 and CEA (12.41 and 7.59 %). Moreover, compared with CEA and CA153, miR-195 had a higher sensitivity for detecting the response to neoadjuvant chemotherapy and significantly increased, more than twofold, after neoadjuvant chemotherapy (P = 0.025, paired t test) in 52.381 % (11/21) of BC cases. However, there were no significant relationships between miR-195 expression and other clinicopathological parameters (TNM stage/pathotype/ER/PR/lymph node status). Our data indicate serum miR-195 is a promising tumor marker for BC diagnosis and general screening, especially for early stage BC. The high sensitivity of miR-195 to neoadjuvant chemotherapy may lay the foundation for future studies on the use of miRNA-based methods for monitoring BC treatment and therapy.

Deregulated microRNAs and Adiponectin in Postmenopausal Women with Breast Cancer

“…It was found that serum miR-195-5p was significantly over-expressed in BC patients, and was associated with some biopathological features, such as histologic type and grade. Patients with lobular and poorly differentiated tumors had higher se- However, some other studies indicated decreased miR-195 levels compared to controls [30,31]. Interestingly, it was also found that miR-195 expression had a significant relationship with IGF-I and IGF-II.…”

Serum miR-195 is a diagnostic and prognostic marker for osteosarcoma

“…Similar with other miRNAs, the expression patterns and functions of miR-195 may both be different in various types of cancer with a tissue-specific manner. For example, Zhao et al [16] reported that serum miR-195 was downregulated in breast cancer and was a potential marker for the diagnosis of this disease; Guo et al [17] demonstrated a tumor suppressive role of miR-195 in nonesmall cell lung cancer; Wang et al [18] indicated that miR-195 had a suppressive role in colorectal cancer and was able to inhibit cancer cell proliferation, colony-formation, and invasion. In contrast, Zanette et al [27] using the TaqMan miRNA assays identified miR-195 as one of highly expressed miRNAs in chronic lymphocytic leukemias.…”

Development of a deregulating MicroRNA panel for the detection of early relapse in postoperative colorectal cancer patients

“…Several previous studies have indicated that miR-93, miR-195, and members of the let-7 family of miRs are downregulated in lung cancer, CRC, and melanoma tissues as compared with normal tissue, suggesting that these miRs are tumor suppressors [29][30][31][32][33][34][35][36][37]. miR-93 can suppress the proliferation of human colon cancer cells and colon cancer stem cells, with worse OS being associated with low miR-93 expression in CRC patients [37,38].…”

“…miR-93 can suppress the proliferation of human colon cancer cells and colon cancer stem cells, with worse OS being associated with low miR-93 expression in CRC patients [37,38]. miR-195 can suppress tumor cell proliferation and metastasis by targeting several proteins, including BCOX1, BCL-2, and CARMA3 [32][33][34]. The overexpression of let-7b in vitro can downregulate cell-cycle-related proteins, including cyclin D1, cyclin D3, cyclin-dependent kinase 4, and the high-mobility group protein and oncogene [30,39].…”